5-Ethynyluracil
5-Ethynyluracil Uses, Dosage, Side Effects, Food Interaction and all others data.
5-Ethynyluracil, which was previously under development by GlaxoSmithKline (GSK), is being developed by Adherex to enhance the therapeutic value and effectiveness of 5-fluorouracil (5-FU), one of the world’s most widely-used oncology agents. 5-FU is widely used in the U.S. and is often first or second line therapy for a variety of cancers including colorectal, breast, gastric, head and neck, ovarian and basal cell cancer of the skin. 5-Ethynyluracil could improve 5-FU by increasing its effectiveness, reducing its side effects and/or making it orally available. 5-Ethynyluracil has received Orphan Drug status from the FDA for the treatment of hepatocellular cancer in combination with fluoropyrimidines (including 5-FU).
5-Ethynyluracil is an orally active dihydropyrimidine dehydrogenase (DPD) inhibitor, designed to enhance activity of chemotaxic agents. It is under investigation by Adherex, under license from GlaxoSmithKline, for the treatment of cancer in combination with 5-fluorouracil (5-FU).
| Trade Name | 5-Ethynyluracil |
| Generic | Eniluracil |
| Eniluracil Other Names | 5-Ethynyluracil, Eniluracil |
| Type | |
| Formula | C6H4N2O2 |
| Weight | Average: 136.1082 Monoisotopic: 136.027277382 |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
For the treatment of cancer in combination with 5-fluorouracil.
How 5-Ethynyluracil works
Normally, 5-FU is rapidly broken down in the body by an enzyme known as dihydropyrimidine dehydrogenase (DPD). 5-Ethynyluracil irreversibly inhibits DPD, thereby substantially slowing the breakdown of 5-FU and prolonging exposure of the tumor cells to the drug.
Innovators Monograph
You find simplified version here 5-Ethynyluracil
